NCT04952272招募中1 期
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年3月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors
研究概览
简要总结
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
详细描述
- Percutaneous microwave ablation or intratumor injection of drug-eluting beads to destroy cancer cells to release tumor-specific antigens
- Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40
- Assessing side effects and therapeutic efficacy after the combined treatments
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Solid advanced malignant tumors
- •Age between18 and 80 years
- •Life expectancy is greater than three months
排除标准
- •Benign tumor
- •Life expectancy is less than three months
- •Serious medical comorbidity
结局指标
主要结局
Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors
时间窗: up to 36 months
Assessing incidence of side effects and primary clinical response of the intratumor injection of CpG-ODN and therpeutical in situ tumor antigen release for advanced tumors, including CR, PR, SD, and PD.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Randomized Phase 2 With CpG-ODN in Malignant GlioblastomaGlioblastomaNCT00190424Assistance Publique - Hôpitaux de Paris80
Unknown
1 期
Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor LinesDiffuse Intrinsic Pontine GliomaNCT02840123Fundació Sant Joan de Déu10
已完成
1 期
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade LymphomasNon-Hodgkin LymphomaMycosis FungoidesNCT00185965Ronald Levy30
撤回
1 期
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.Mycosis FungoidesNCT00226993Stanford University
进行中（未招募）
1 期
Intratumoral PH-762 for Cutaneous CarcinomaSquamous Cell Carcinoma of the SkinMalignant Melanoma of SkinMerkel Cell Carcinoma of SkinNCT06014086Phio Pharmaceuticals Inc.30